Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Chardan Capital Maintains Buy on Provention Bio, Lowers Price Target to $25

By Benzinga Newsdesk
March 13, 9:10 AM
Chardan Capital analyst Geulah Livshits maintains Provention Bio (NASDAQ:PRVB) with a Buy and lowers the price target from $30 to $25.

PRVB

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • Movers
  • News
  • Small Cap
  • Top Stories

Why Prevention Bio Stock Is Rocketing Past 52-Week Highs Today

By Adam Eckert
March 13, 8:44 AM
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company.</

PRVB

Read More
4 minute read
  • Economics
  • Federal Reserve
  • Futures
  • Markets
  • Pre-Market Outlook
  • Previews
  • Small Cap
  • Top Stories
  • Trading Ideas

Nasdaq Futures Climb Solidly After Past Week’s Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows

By Shanthi Rexaline
March 13, 6:55 AM
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis.

AMGN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • Movers
  • News
  • Trading Ideas

Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B

By Benzinga Newsdesk
March 13, 4:08 AM
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367

PRVB

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Provention Bio, Lowers Price Target to $16

By Benzinga Newsdesk
February 15, 7:20 AM
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Provention Bio (NASDAQ:PRVB) with a Buy and lowers the price target from $18 to $16.

PRVB

Read More
1 minute read
  • Biotech
  • General
  • News

UnitedHealth Is Now Providing Insurance Coverage For Prevention Bio’s Tzield (For The Delay Of Diabetes) Effective February 1

By Happy Mohamed
February 1, 4:35 PM
https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/tzield.pdf

PRVB

Read More
1 minute read
  • Events
  • News
  • Rumors
  • Trading Ideas

Watching Provention Bio; Shares Move Lower As Co Showcases Webinar Titled ‘Tzield: Learn More About A Newly Approved Therapy’

By Benzinga Newsdesk
January 18, 1:56 PM
https://members.amcp.org/AMCP2019/Events/Event_Display.aspx?EventKey=GTW_230118&WebsiteKey=2bfc55cc-0861-4d8b-91d1-9a8c0f748666

PRVB

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

‘Provention Bio’s Recently Approved Drug Tzield (Teplizumab) For The Delay Of Clinical Type 1 Diabetes Has Been Added To The Department Of Veterans Affairs National Acquisition Center Drug Catalog’

By Benzinga Newsdesk
January 17, 12:52 PM
https://www.vendorportal.ecms.va.gov/NAC/Pharma/Details?NDC=73650031601&CNT=36F79723D017E  

PRVB

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
December 29, 2:04 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ALGN

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
December 12, 1:52 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

A

Posts pagination

Previous 1 2 3 … 6 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service